ORICORIC Pharmaceuticals Inc

Citigroup lowered their price objective on shares of Oric Pharmaceuticals from $17.00 to $16.00 and set a 'buy' rating on the stock in a research report on Tuesday...

Oric Pharmaceuticals (NASDAQ:ORIC - Get Free Report) issued its quarterly earnings results on Monday. The company reported ($0.34) earnings per share for the quarter, missing analysts' consensus estimates of ($0.31) by ($0.03...

Oric Pharmaceuticals, Inc. (NASDAQ:ORIC - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the fourteen ratings firms that are presently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, two have assigned...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC...

Oric Pharmaceuticals (NASDAQ:ORIC) will be releasing its Q1 2026 earnings before the market opens on Monday, May 4. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-4-oric-pharmaceuticals-inc-stock...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC...

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors ofORIC Pharmaceuticals, Inc. (Oricor the Company) (NASDAQ:ORIC) for violations of the securities laws.The investigation focuses on whether the Company issued false...

Oric Pharmaceuticals (NASDAQ:ORIC) Trading Up 6.5% - Here's Why...

Shares of Oric Pharmaceuticals, Inc. (NASDAQ:ORIC - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the fourteen brokerages that are currently covering the company...